◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Kymera Therapeutics Inc (KYMR) EBITDA 2018–TTM

Name: Kymera Therapeutics Inc (KYMR) ebitda history 2018-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-08-16

Kymera Therapeutics Inc annual ebitda for fiscal 2025 was -$303 million, a decrease of 40.3% from -$216 million in fiscal 2024. All figures are reported results from public filings — no estimates or projections.

KYMR Annual EBITDA

EBITDA (annual)	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
EBITDA	—	($303M)	($216M)	($143M)	($152M)	($98M)	($44M)	($40M)	($21M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

KYMR Quarterly EBITDA

EBITDA (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
EBITDA	—	($67M)	($85M)	($79M)	($74M)	($63M)	($69M)	($60M)	($40M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EBITDA at Comparable Companies

PRAX EBITDA — Praxis Precision Medicines Inc
APGE EBITDA — Apogee Therapeutics, Inc. Common Stock
PTGX EBITDA — Protagonist Therapeutics Inc
KRYS EBITDA — Krystal Biotech Inc
IONS EBITDA — Ionis Pharmaceuticals Inc
SYRE EBITDA — Spyre Therapeutics Inc.

More KYMR metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow · Shares Outstanding

All KYMR financial statements → Interactive KYMR charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.